Berlin, Germany, July 21, 2021– The European Commission has granted marketing authorization in the E
Erfahren Sie mehr 2021-07-26Nachrichtenliste
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
USFDA approves KIT inhibitor Ayvakit (Avatinib)
CStone's partner Blueprint Medicines recently announced that the U.S. Food and Drug Administrati
Erfahren Sie mehr 2021-06-24
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week®(DDW) Virtual
Erfahren Sie mehr 2021-06-01
Xofluza was approved in China
On April 29, 2021, Roche China announced that its innovative influenza drug Xofluza® (Mabaloxavir) h
Erfahren Sie mehr 2021-05-13
Tagrisso approved in China in early lung cancer
AstraZeneca'sTagrisso(osimertinib) has been approved in China for the adjuvant treatment of pati
Erfahren Sie mehr 2021-04-15
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA t
Erfahren Sie mehr 2021-03-15
BeiGene Announces EMA Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with WM
On June 18, 2020, BeiGene, Ltd. (“BeiGene” or the “Company”), a commercial-stage biotechnology compa
Erfahren Sie mehr 2021-02-25
VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China
January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natri
Erfahren Sie mehr 2021-02-08
Progress in the development of new and efficient diabetes treatment drugs
Recently, Wang Junfeng's research team from Hefei Institute of Material Science, Chinese Academy
Erfahren Sie mehr 2021-01-19
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.
Erfahren Sie mehr 2020-12-22